Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group
Catherine Dunn, Wei Hong, Peter Gibbs, Stephen Ackland, Katrin Sjoquist, Niall C Tebbutt, Timothy Price, Matthew Burge
CLINICAL COLORECTAL CANCER | CIG MEDIA GROUP, LP | Published : 2021
Palliative chemotherapy is the cornerstone of treatment for the majority of patients with metastatic colorectal cancer, with the aim of increasing length and quality of life. Although guidelines outline the available treatment options in the first line, they provide limited guidance on choice and intensity of the chemotherapy backbone. Data from the TRIBE and TRIBE2 studies confirm a survival benefit with triplet FOLFOXIRI and bevacizumab, and this is a preferred option for younger patients with good performance status able to tolerate it. However, the relative benefit of a fluoropyrimidine doublet with oxaliplatin or irinotecan over single-agent fluoropyrimidine with or without a biologic i..View full abstract
Supported by an educational grant from Servier to the Australasian Gastrointestinal Trials Group.